LCTX vs PROK
LCTX: Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships with major pharmaceutical companies. PROK: ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in Phase 3 trials with FDA RMAT designation.
Side-by-side fundamentals
| Metric | LCTX | PROK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.11 | $1.53 | |
| Market cap as of 2026-07-23 | $278M | $462M | |
| PEG as of 2026-07-23 | -0.02 | n/a | |
| Net margin as of 2026-07-23 | -431.2% | -8131.5% | LCTX higher |
| Gross margin as of 2026-07-23 | +94.1% | n/a | |
| Operating margin as of 2026-07-23 | -256.5% | -18959.7% | LCTX higher |
| ROE as of 2026-07-23 | -151.3% | -28.1% | PROK higher |
| ROA as of 2026-07-23 | -63.3% | -21.4% | PROK higher |
| Debt / equity as of 2026-07-23 | 0.00 | 5.40 | LCTX lower |
| Revenue growth (YoY) as of 2026-07-23 | -37.1% | +190.5% | PROK higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | n/a | |
| Beta as of 2026-07-23 | 1.51 | 1.81 | |
| 1-year return as of 2026-07-22 close | +16.8% | -49.8% | LCTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.